Urinary diversion disparity following radical cystectomy for bladder cancer in the Hispanic population.

To determine if disparities in quality of surgical care exist between Hispanics and non-Hispanics undergoing radical cystectomy for bladder cancer.

An observational cohort study was conducted retrospectively on patients who underwent radical cystectomy for urothelial carcinoma of the bladder at our institution between January 2005 and July 2018. Data was collected on demographic, clinical, and pathological characteristics of patients, including self-reported ethnicity. Univariable and multivariable logistic or linear regression analyses were used to evaluate the association of ethnicity with receipt of neoadjuvant chemotherapy, utilization of laparoscopic surgery, number of lymph nodes removed, and continent urinary diversion.

We identified 507 patients in our database out of which, 136 (27%) were Hispanic and 371 (73%) were non-Hispanic. Compared to non-Hispanics, Hispanics had a higher BMI (26.9 kg/m2 vs. 28.2 kg/m2, p=0.006) and lived further away from site of surgery (34 vs. 96 miles, p=0.02). No significant differences were observed in receipt of neoadjuvant chemotherapy, laparoscopic surgery, or number of lymph nodes removed during cystectomy between ethnicity groups. However, Hispanics were less likely than non-Hispanics to receive a continent urinary diversion on multivariable analysis (OR 0.30, 95% CI 0.10-0.92, p=0.03).

Disparity exists in the delivery of continent urinary diversions for Hispanic patients undergoing radical cystectomy for bladder cancer. Further investigation is needed to determine the potential causes for this disparity in care delivered.

Urology. 2019 Dec 26 [Epub ahead of print]

Emily M Rios, Mitchell A Parma, Roman A Fernandez, Timothy N Clinton, Ryan M Reyes, Dharam Kaushik, Deepak Pruthi, Ahmed M Mansour, Neelam Mukherjee, Jon Gelfond, Karen M Wheeler, Robert S Svatek

Department of Urology, University of Texas Health San Antonio (UTHSA)., Department of Biostatistics, UTHSA., Experimental Development Therapeutics Program/Urology, MD Anderson Cancer Center/UT Health Science Center., Department of Urology, University of Texas Health San Antonio (UTHSA); Experimental Development Therapeutics Program/Urology, MD Anderson Cancer Center/UT Health Science Center., Department of Urology, University of Texas Health San Antonio (UTHSA); Experimental Development Therapeutics Program/Urology, MD Anderson Cancer Center/UT Health Science Center. Electronic address: .